Work

Cabotégravir + rilpivirine à longue durée d'action tous les 2 mois : résultats d'ATLAS 2M à 152 semaines

Year: 2022

Type: article

Study design: Clinical Trial

Source: Médecine et Maladies Infectieuses Formation

DOI: 10.1016/j.mmifmc.2022.03.279

Authors: J. Reynes, E. Overton, A. Thalme, A. Wong, N. Porteiro, C. Español, C. Acuipil, R. D'amico, K. Vandermeulen, W. Spreen

Institutions: Centre Hospitalier Universitaire de Montpellier, University of Alabama at Birmingham, Karolinska University Hospital, University of Regina, University of Saskatchewan, GlaxoSmithKline (United Kingdom), Janssen (Belgium)

Language: French

Topic: HIV/AIDS drug development and treatment

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4387943866

FWCI:

Cites:

Cited by:

Related to: 10